Abstract
About one-half of the patients with congestive heart failure have preserved left ventricular ejection fraction (HFpEF). Although the etiology of HFpEF is most commonly related to long-standing hypertension and atherosclerosis, a significant number of suspected HFpEF patients have a restrictive cardiomyopathy or chronic pericardial disease. Recognizing these syndromes is important because early diagnosis may lead to instituting specific therapy that may prolong survival, improve quality of life, and/or recognize and treat an underlying systemic disorder. Advances in diagnostic imaging, biomarkers, and genetic testing today allow identification of the specific etiology in most cases. Novel pharmacological, immunologic, and surgical therapies are leading to improved quality of life and survival.
Original language | English (US) |
---|---|
Pages (from-to) | 2061-2076 |
Number of pages | 16 |
Journal | Journal of the American College of Cardiology |
Volume | 67 |
Issue number | 17 |
DOIs | |
State | Published - May 3 2016 |
Keywords
- amyloidosis
- echocardiography
- endomyocardial fibrosis
- heart failure
- magnetic resonance imaging
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine